To include your compound in the COVID-19 Resource Center, submit it here.

Mekinist trametinib: Phase II started

NIH's National Cancer Institute (NCI) began the single-blind Phase II M-PACT trial to evaluate whether treatment based on specific gene mutations improves the rate and duration of response in patients with advanced, refractory solid tumors. NCI said trials conducted by other companies randomly assign patients

Read the full 453 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers